Cibus (CBUS) 10-Q 5 Aug 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 05, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Trading Symbol	CLXT
Entity Registrant Name	Calyxt, Inc.
Entity Central Index Key	0001705843
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		37,270,998
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-38161
Entity Tax Identification Number	27-1967997
Entity Address, Address Line One	2800 Mount Ridge Road
Entity Address, City or Town	Roseville
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55113-1127
City Area Code	651
Local Phone Number	683-2807
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock (0.0001 par value)
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 17,489	$ 17,299
Short-term investments	0	11,698
Restricted cash	393	393
Accounts receivable	3,994	4,887
Inventory	2,468	1,383
Prepaid expenses and other current assets	629	3,930
Total current assets	24,973	39,590
Non-current restricted cash	598	597
Land, buildings, and equipment	21,998	22,860
Other non-current assets	207	280
Total assets	47,776	63,327
Current liabilities:
Accounts payable	2,183	929
Accrued expenses	2,326	2,891
Accrued compensation	2,093	1,950
Due to related parties	128	766
Current portion of financing lease obligations	380	364
Other current liabilities	46	45
Total current liabilities	7,156	6,945
Financing lease obligations	17,682	17,876
Long-term debt	0	1,518
Other non-current liabilities	1,042	113
Total liabilities	25,880	26,452
Stockholders’ equity:
Common stock, $0.0001 par value; 275,000,000 shares authorized; 37,305,625 shares issued and 37,205,473 shares outstanding as of June 30, 2021, and 37,165,196 shares issued and 37,065,044 shares outstanding as of December 31, 2020	4	4
Additional paid-in capital	204,663	204,807
Common stock in treasury, at cost; 100,152 shares as of June 30, 2021, and December 31, 2020	(1,043)	(1,043)
Accumulated deficit	(181,728)	(166,893)
Total stockholders’ equity	21,896	36,875
Total liabilities and stockholders’ equity	$ 47,776	$ 63,327

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	275,000,000	275,000,000
Common stock, shares issued	37,305,625	37,165,196
Common stock, shares outstanding	37,205,473	37,065,044
Treasury stock, shares	100,152	100,152

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenue	$ 11,880	$ 2,307	$ 16,282	$ 4,684
Cost of goods sold	11,527	5,321	18,272	9,205
Gross margin	353	(3,014)	(1,990)	(4,521)
Operating expenses:
Research and development	2,844	2,825	5,894	5,612
Selling, general, and administrative	3,478	5,167	7,736	11,465
Management fees	15	42	45	104
Total operating expenses	6,337	8,034	13,675	17,181
Loss from operations	(5,984)	(11,048)	(15,665)	(21,702)
Gain upon extinguishment of Payroll Protection Program Loan	1,528	0	1,528	0
Interest, net	(357)	154	(703)	(244)
Non-operating expenses	6	(8)	5	(19)
Loss before income taxes	(4,807)	(10,902)	(14,835)	(21,965)
Income taxes
Net loss	$ (4,807)	$ (10,902)	$ (14,835)	$ (21,965)
Basic and diluted net loss per share	$ (0.13)	$ (0.33)	$ (0.40)	$ (0.67)
Weighted average shares outstanding - basic and diluted	37,199,349	33,039,338	37,168,018	33,013,739
Anti-dilutive stock options, restricted stock units, and performance stock units	5,223,327	5,140,153	5,223,327	5,140,153

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDER'S EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Shares in Treasury [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning balance at Dec. 31, 2019	$ 62,508	$ 3	$ 185,588	$ (1,043)	$ (122,057)	$ 17
Beginning balance, shares at Dec. 31, 2019		32,951,329
Net loss	(21,965)				(21,965)
Stock-based compensation	3,068		3,068
Issuance of common stock, shares		106,983
Shares withheld for net share settlement, shares		(17,792)
Other comprehensive income (loss)	(58)					(58)
Ending balance at Jun. 30, 2020	43,553	$ 3	188,656	(1,043)	(144,022)	(41)
Ending balance, shares at Jun. 30, 2020		33,040,520
Beginning balance at Mar. 31, 2020	52,536	$ 3	186,859	(1,043)	(133,120)	(163)
Beginning balance, shares at Mar. 31, 2020		32,990,647
Net loss	(10,902)				(10,902)
Stock-based compensation	1,797		1,797
Issuance of common stock, shares		49,873
Other comprehensive income (loss)	122					122
Ending balance at Jun. 30, 2020	43,553	$ 3	188,656	(1,043)	(144,022)	$ (41)
Ending balance, shares at Jun. 30, 2020		33,040,520
Beginning balance at Dec. 31, 2020	36,875	$ 4	204,807	(1,043)	(166,893)
Beginning balance, shares at Dec. 31, 2020		37,065,044
Net loss	(14,835)				(14,835)
Stock-based compensation	(371)		(371)
Issuance of common stock	227		227
Issuance of common stock, shares		140,429
Ending balance at Jun. 30, 2021	21,896	$ 4	204,663	(1,043)	(181,728)
Ending balance, shares at Jun. 30, 2021		37,205,473
Beginning balance at Mar. 31, 2021	25,605	$ 4	203,565	(1,043)	(176,921)
Beginning balance, shares at Mar. 31, 2021		37,163,187
Net loss	(4,807)				(4,807)
Stock-based compensation	1,079		1,079
Issuance of common stock	19		19
Issuance of common stock, shares		42,286
Ending balance at Jun. 30, 2021	$ 21,896	$ 4	$ 204,663	$ (1,043)	$ (181,728)
Ending balance, shares at Jun. 30, 2021		37,205,473

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating activities
Net loss	$ (14,835,000)	$ (21,965,000)
Adjustments to reconcile net loss to net cash used by operating activities:
Gain upon extinguishment of Payroll Protection Program Loan	(1,528,000)	0
Depreciation and amortization	1,180,000	904,000
Stock-based compensation	(371,000)	3,068,000
Changes in operating assets and liabilities:
Accounts receivable	893,000	(1,289,000)
Due to/from related parties	(638,000)	(598,000)
Inventory	(1,085,000)	(2,688,000)
Prepaid expenses and other current assets	3,301,000	(1,118,000)
Accounts payable	1,254,000	(505,000)
Accrued expenses	(555,000)	(546,000)
Accrued compensation	143,000	(888,000)
Other	992,000	(26,000)
Net cash used by operating activities	(11,249,000)	(25,651,000)
Investing activities
Sales and (purchases) of short-term investments, net	11,698,000	(29,942,000)
Purchases of land, buildings, and equipment	(307,000)	(525,000)
Net cash provided by (used by) investing activities	11,391,000	(30,467,000)
Financing activities
Proceeds from Payroll Protection Program loan		1,518,000
Repayments of financing lease obligations	(178,000)	(130,000)
Proceeds from the exercise of stock options	227,000	0
Net cash provided by financing activities	49,000	1,388,000
Net increase (decrease) in cash, cash equivalents, and restricted cash	191,000	(54,730,000)
Cash, cash equivalents, and restricted cash - beginning of period	18,289,000	60,038,000
Cash, cash equivalents, and restricted cash – end of period	$ 18,480,000	$ 5,308,000

Basis of Presentation & Summary

Basis of Presentation & Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation & Summary of Significant Accounting Policies	1. BASIS OF PRESENTATION & SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Our unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP or GAAP) for interim financial information and with the rules and regulations of the Securities and Exchange Commission (SEC) applicable to interim financial statements. In our opinion, the accompanying consolidated financial statements reflect all adjustments necessary for a fair presentation of our statements of financial position, results of operations, and cash flows for the periods presented but they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Except as otherwise disclosed herein, these adjustments consist of normal recurring items. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole or any other interim period. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the consolidated financial statements and during the reporting period. Actual results could materially differ from these estimates. Certain prior year amounts have been reclassified to conform to the current year presentation. For further information, refer to the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 4, 2021. The accompanying Balance Sheet as of December 31, 2020, was derived from the audited consolidated financial statements. This Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and notes included in the Annual Report on Form 10-K for the year ended December 31, 2020. Risks and Uncertainties Considering factors such as our anticipated cash receipts from sales of grain and our product development and technology licensing efforts with partners, our anticipated cash burn rate, and our expense reduction efforts, we believe our cash, cash equivalents, and restricted cash as of June 30, 2021, will be sufficient to fund our operations for at least the next twelve months and into the second half of 2022. We anticipate that we will continue to generate losses for the next several years before revenue is enough to support our operating capital requirements. Until we can generate substantial cash flow, we expect to finance a portion of future cash needs through cash on hand, commercialization activities, which may result in various types of revenue streams from seed sales and future development agreements, trait licenses, and technology licenses, including upfront and milestone payments, annual license fees, and royalties, government or other third-party funding, and public or private equity or debt financings. However, additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in enough amounts or on terms acceptable to us, we may have to significantly delay, scale back, or discontinue the development or commercialization of our activities. Failure to receive additional funding could cause us to cease operations, in part or in full. If we raise additional funds through the issuance of additional debt or equity securities, it could result in dilution to our existing stockholders and increased fixed payment obligations, and these securities may have rights senior to those of our shares of common stock. Any of these events could significantly harm our business, financial condition, and prospects. Net Loss Per Share All anti-dilutive stock options, restricted stock units, and performance stock units are excluded from the calculation of net loss per share. Due to our net loss position for the three and six months ended June 30, 2021, and June 30, 2020 , all of our outstanding stock options, restricted stock units, and performance stock units are considered anti-dilutive and excluded from the calculation of net loss per share. Accordingly, the treasury method was not used in determining the number of anti-dilutive stock options and restricted stock units.

Financial Instruments Measured

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk	6 Months Ended
	Jun. 30, 2021
Text Block [Abstract]
Financial Instruments Measured at Fair Value and Concentrations of Credit Risk	2. FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE AND CONCENTRATIONS OF CREDIT RISK Financial Instruments Measured at Fair Value and Financial Statement Presentation Financial instruments including cash and cash equivalents, restricted cash, accounts payable, and all other current liabilities have carrying values that approximate fair value. We measure short-term investments and commodity derivative contracts at fair value on a recurring basis. The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as of the measurement date as follows: Level 1: Fair values are based on unadjusted quoted prices in active trading markets for identical assets and liabilities. Level 2: Fair values are based on observable quoted prices other than those in Level 1, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets. Level 3: Fair values are based on at least one significant unobservable input for the asset or liability. Fair Value Measurements and Financial Statement Presentation The fair values of our financial instruments measured at fair value and their respective levels in the fair value hierarchy as of June 30, 2021, and December 31, 2020, were as follows: June 30, 2021 June 30, 2021 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Commodity derivative contracts $ 1 $ — $ — $ 1 $ — $ — $ — $ — Total $ 1 $ — $ — $ 1 $ — $ — $ — $ — December 31, 2020 December 31, 2020 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Short-term investments $ 11,698 $ — $ — $ 11,698 $ — $ — $ — $ — Commodity derivative contracts 467 — — 467 — — — — Total $ 12,165 $ — $ — $ 12,165 $ — $ — $ — $ — The non-current portion of our financing lease obligations are also considered a financial instrument, which we measure at fair value for disclosure purposes. It is a Level 2 liability and had a fair value of $ 14.9 million as of June 30, 2021 , and a fair value of $ 15.2 million as of December 31, 2020. Commodity Price Risk We enter into seed and grain production agreements with settlement values based on commodity futures market prices (Forward Purchase Contracts). These Forward Purchase Contracts allow the counterparty to fix their sales prices at various times as defined in the contract. Because we intend to take physical delivery under the Forward Purchase Contracts, we have grain inventory we will need to sell. We intend to sell these inventories at then-current market prices. As a result, when the Forward Purchase Contract counterparty fixes their grain prices, we enter hedging arrangements by selling futures contracts which converts our exposure to these fixed prices to floating prices. We expect to maintain these hedging relationships until such grain inventory is sold to help stabilize our margins. We do not account for these economic hedges as accounting hedges. We expect any gains or losses from these hedging arrangements to be offset by gains or losses on the grain inventories when such grain inventories are sold. As of June 30, 2021 , we held commodity contracts with a notional amount of $ 8.0 million. As of June 30, 2021, those commodity contracts carried an unrealized loss of $ 1.0 million that had been recognized in earnings over the period from their acquisition to June 30, 2021, and that may be realized in the future depending upon the timing of the liquidation of those positions which is based on our future grain sales and changes in soybean prices. Prior to August 1, 2020, we designated all our commodity derivative contracts as cash flow hedges based on the nature of our business activities. As a result, all gains or losses associated with recording those commodity derivative contracts at fair value were recorded as a component of accumulated other comprehensive income (loss) (AOCI). We reclassified amounts from AOCI to cost of goods sold when we sold the underlying products to which those hedges related. For the three and six months ended June 30, 2020, we reclassified an immaterial amount from AOCI to cost of goods sold, and there were no such reclassifications in the same period in 2021. Foreign Exchange Risk Foreign currency fluctuations affect our foreign currency cash flows related primarily to payments to Cellectis. Our principal foreign currency exposure is to the euro. We do not hedge these exposures, and we do not believe that the current level of foreign currency risk is significant to our operations. Concentrations of Credit Risk We invest our cash, cash equivalents, and restricted cash in highly liquid securities and investment funds. We diversify the risk posed by exceeding deposit insurance limits by allocating from time-to-time certain investments to a diverse portfolio of short-dated, high investment-grade securities, which we classify as short-term investments that are recorded at fair value in our consolidated financial statements. We ensure the credit risk in this portfolio is in accordance with our internal policies and if necessary, make changes to investments to ensure credit risk is minimized. We have not experienced any counterparty credit losses. As of June 30, 2021, we did not hold any short-term investments.

Related-Party Transactions

Related-Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related-Party Transactions	3. RELATED-PARTY TRANSACTIONS We have several agreements that govern our relationship with Cellectis, some of which require us to make payments to Cellectis. Pursuant to our management services agreement with Cellectis, we incurred nominal management fee expenses for the three and six months ended June 30, 2021, and 2020. Cellectis has also guaranteed the lease agreement for our headquarters. Cellectis’ guarantee of our obligations under the lease will terminate at the end of the second consecutive calendar year in which our tangible net worth exceeds $ 300 million. TALEN ® is our primary gene editing technology, and it is the foundation of our technology platform. TALEN ® technology was invented by researchers at the University of Minnesota and Iowa State University and exclusively licensed to Cellectis. We obtained an exclusive license for the TALEN ® technology for commercial use in plants from Cellectis. We also license other technology from Cellectis. We owe Cellectis royalties on any revenue we generate from sales of products less certain amounts as defined in the license agreement, royalties on certain cumulative revenue thresholds, and a percentage of any sublicense revenues. We have incurred nominal license and royalty fees for the three and six months ended June 30, 2021, and 2020. We have entered into various agreements with the University of Minnesota, pursuant to which we have been granted both exclusive and non-exclusive license agreements that carry annual license fees, milestone payments, royalties, and associated legal fees. These agreements primarily relate to gene-editing tools, enabling technologies and germplasm. We incurred nominal expenses pursuant to these agreements for the three and six months ended June 30, 2021, and 2020.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	4. STOCK-BASED COMPENSATION We use broad-based stock plans to attract and retain highly qualified officers and employees and to help ensure that management’s interests are aligned with those of our shareholders. We have also granted equity-based awards to directors, nonemployees, and certain employees of Cellectis. In December 2014, we adopted the Calyxt, Inc. Equity Incentive Plan (2014 Plan), which allowed for the grant of stock options, and in June 2017, we adopted the 2017 Omnibus Plan (2017 Plan), which allowed for the grant of stock options, restricted stock units, performance stock units and other types of equity awards. On February 19, 2021, James Blome ceased serving as our Chief Executive Officer. We recorded a benefit to earnings from a $ 2.5 million recapture of non-cash stock compensation expense from the forfeiture of Mr. Blome’s unvested stock options, restricted stock units, and performance stock units. As of June 30, 2021 , 1,634,125 shares were registered and available for grant under effective registration statements, while 5,950,199 shares were available for grant in the form of stock options, restricted stock, restricted stock units, and performance stock units under the 2017 Plan. On July 16, 2021, we filed a Registration Statement on Form S-8 with the SEC which registered an additional 4,299,904 shares of common stock that may be issued or delivered and sold pursuant to the 2017 Plan and 600,000 shares of common stock that may be issued or delivered and sold pursuant to the Calyxt, Inc. Employee Inducement Incentive Plan (the Inducement Plan). The Inducement Plan shares of common stock are issuable upon the settlement of performance stock units which were granted to Mr. Carr as a material inducement to accept employment as our President and Chief Executive Officer. Stock-based awards currently outstanding also include awards granted under the 2014 Plan, under which no further awards will be granted. Stock Options The estimated fair values of stock options granted, and the assumptions used for the Black-Scholes option pricing model were as follows: Six Months Ended June 30, 2021 2020 Estimated fair values of stock options granted $ 4.54 $ 5.19 Assumptions: Risk-free interest rate 0.6 % - 1.1 % 1.7 % Expected volatility 80.1 % - 82.0 % 77.4 % Expected term (in years) 5.5 - 6.5 6.9 We estimate the fair value of each option on the grant date, or other measurement dates if applicable, using a Black-Scholes option-pricing model, which requires us to make predictive assumptions regarding employee exercise behavior, future stock price volatility, and dividend yield. Our expected term represents the period that options granted are expected to be outstanding determined using the simplified method. We estimate our future stock price volatility using the historical volatility of comparable public companies over the expected term of the option. We estimate the risk-free interest rate based on the United States Treasury zero-coupon yield curve at the date of grant for the expected term of the option. We do not nor do we expect to pay dividends. Option strike prices are set at 100 percent or more of the closing share price on the date of grant, and generally vest over three to six years following the grant date. Options generally expire 10 years after the date of grant. Information on stock option activity is as follows: Options Weighted- Options Weighted- Balance as of December 31, 2020 2,347,663 $ 10.15 4,621,173 $ 10.30 Granted 456,959 5.71 Exercised ( 61,372 ) 3.70 Forfeited or expired ( 550,110 ) 10.57 Balance as of June 30, 2021 2,412,501 $ 10.49 4,466,650 $ 9.89 Stock-based compensation expense related to stock option awards is as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Stock-based compensation expense $ 800 $ 1,246 $ 405 $ 2,252 As of June 30, 2021 , options outstanding and exercisable had an aggregate intrinsic value of $ 0.4 million and the weighted average remaining contractual term was 5.8 years. Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Net cash proceeds $ 19 $ — $ 227 $ — Intrinsic value of options exercised $ 13 $ — $ 344 $ — As of June 30, 2021 , unrecognized compensation expense related to non-vested stock options was $ 6.7 million. This expense will be recognized over 28 months on average. Restricted Stock Units We grant restricted stock units which generally vest over three to five years after the date of grant. Information on restricted stock unit activity is as follows: Number of Weighted- Unvested balance at December 31, 2020 547,807 $ 9.49 Granted 234,504 5.61 Vested ( 69,323 ) 9.25 Forfeited ( 133,348 ) 12.49 Unvested balance at June 30, 2021 579,640 $ 7.26 The total grant-date fair value of restricted stock unit awards that vested is as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Grant-date fair value $ 390 $ 660 $ 641 $ 1,170 Stock-based compensation expense related to restricted stock units is as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Stock-based compensation expense $ 228 $ 441 $ ( 521 ) $ 596 As of June 30, 2021 , unrecognized compensation expense related to restricted stock units was $ 2.1 million. This expense will be recognized over 24 months on average. We treat stock-based compensation awards granted to employees of Cellectis as deemed dividends. We recorded deemed dividends as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Deemed dividends from grants to Cellectis employees $ 107 $ 198 $ 28 $ 422 Performance Stock Units In June 2019, we granted 311,667 performance stock units under the 2017 Plan to three executive officers. The performance stock units will vest at 50 %, 100 % or 120 % of the shares under the award at the end of a three-year performance period based upon increases in the value of our common stock from the grant price of $ 12.48 . The performance stock units will be settled in restricted stock upon vesting, with restrictions on transfer lapsing on the second anniversary of the restricted stock issuance date. During the six months ended June 30, 2021, we recognized a benefit from the forfeiture of 166,667 performance stock units held by Mr. Blome, our former chief executive officer. Stock-based compensation expense related to performance stock units is as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Stock-based compensation expense $ 51 $ 110 $ ( 255 ) $ 220 As of June 30, 2021 , unrecognized compensation expense related to performance stock units was $ 0.6 million. This expense will be recognized over 36 months on average.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	5. INCOME TAXES We provide for a valuation allowance when it is more likely than not that we will not realize a portion of the deferred tax assets. We have established a full valuation allowance for deferred tax assets due to the uncertainty that enough taxable income will be generated in the taxing jurisdiction to utilize the assets. Therefore, we have not reflected any benefit of such deferred tax assets in the accompanying consolidated financial statements. As of June 30, 2021, there were no material changes to what we disclosed regarding tax uncertainties or penalties as of December 31, 2020 .

Leases, Other Commitments, and

Leases, Other Commitments, and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Leases, Other Commitments, and Contingencies	6. LEASES, OTHER COMMITMENTS, AND CONTINGENCIES Litigation and Claims We are not currently a party to any material pending legal proceeding. Leases We lease our headquarters facility, office equipment, and other items. Our headquarters lease involved the sale of land and improvements to a third-party who then constructed the facility. This lease is considered a financing lease. We also have an equipment financing arrangement that is considered a financing lease. This arrangement has a term of four years for each draw. We were required to deposit cash into a restricted account in an amount equal to the future rent payments required by the lease. As of June 30, 2021 , restricted cash totaled $ 1.0 million. We have the option to request the return of excess collateral annually in December, and the amount we expect to receive is reflected as a current asset. Rent expense from operating leases was as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Rent expense from operating leases $ 11 $ 23 $ 24 $ 47 Other Commitments As of June 30, 2021 , we have noncancelable commitments to purchase grain and seed from growers at dates throughout 2021 aggregating $ 6.8 million based on current commodity futures market prices, other payments to growers, and estimated yields per acre. This commitment is not recorded in the consolidated financial statements because we have not taken delivery of the seed or grain as of June 30, 2021 .

Supplemental Information

Supplemental Information	6 Months Ended
	Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Information	7. SUPPLEMENTAL INFORMATION Certain balance sheet amounts are as follows: As of June 30, As of December 31, In Thousands 2021 2020 Accounts Receivable: Accounts receivable $ 3,819 $ 4,317 Receivables from growers 175 570 Allowance for doubtful accounts — — Total $ 3,994 $ 4,887 We carry receivables related to amounts we are owed by growers from their purchases of seed. These amounts reduce the cost of the grain we ultimately purchase from the grower and are repaid either on current terms or on an extended payment basis. If a grower has elected extended payment terms, they will pay a higher price per unit and grant us the right to deduct the amount we are owed from the payment we make upon the purchase of their grain. As of June 30, 2021, and December 31, 2020 all of the receivables from growers were on extended payment terms. Certain statements of operations amounts are as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Stock compensation expense: Research and development $ 417 $ 488 $ 809 $ 807 Selling, general, and administrative 662 1,309 ( 1,180 ) 2,261 Total $ 1,079 $ 1,797 $ ( 371 ) $ 3,068 Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Interest, net: Interest expense $ ( 359 ) $ ( 371 ) $ ( 719 ) $ ( 743 ) Interest income 2 525 16 499 Total $ ( 357 ) $ 154 $ ( 703 ) $ ( 244 ) Certain balance sheet and statements of cash flows amounts are as follows: As of June 30, As of December 31, As of June 30, In Thousands 2021 2020 2020 Cash, cash equivalents, restricted cash, and short-term investments: Cash and cash equivalents $ 17,489 $ 17,299 $ 3,875 Restricted cash 393 393 393 Non-current restricted cash 598 597 1,040 Total cash, cash equivalents, and restricted cash 18,480 18,289 5,308 Short-term investments — 11,698 29,942 Total $ 18,480 $ 29,987 $ 35,250

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Segment Information	8. SEGMENT INFORMATION We operate in a single reportable segment, the development and commercialization of products derived from plant cells. Products commercialized to date have included a soybean and its derivative products, including oil and meal. Our current commercial focus is North America.

Long-Term Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Long-Term Debt	9. LONG-TERM DEBT Our long-term debt was comprised of a $ 1.5 million promissory note pursuant to the Paycheck Protection Program (the PPP loan) established by the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) implemented by the U.S. Small Business Administration (SBA). We received the funds under the PPP loan on April 19, 2020. Subject to certain conditions, the PPP loan and accrued interest were eligible to be forgiven in whole or in part by applying for forgiveness pursuant to the CARES Act and the Paycheck Protection Program. In order to be eligible for forgiveness, the proceeds of the PPP loan were required to be applied to certain eligible expenses, including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments, with not more than 40 percent of the amount applied to non-payroll costs. We applied the proceeds from the PPP loan toward qualifying expenses. On October 21, 2020, as modified December 29, 2020, we applied for forgiveness of the full principal amount and all accrued interest. O n April 8, 2021, we were notified by the SBA that the full principal amount and all accrued interest of the PPP loan had been forgiven. Accordingly, we recognized a gain upon the extinguishment of the PPP loan for $ 1.5 million in the three months ended June 30, 2021.

Basis of Presentation & Summa_2

Basis of Presentation & Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Net Loss Per Share	Net Loss Per Share All anti-dilutive stock options, restricted stock units, and performance stock units are excluded from the calculation of net loss per share. Due to our net loss position for the three and six months ended June 30, 2021, and June 30, 2020 , all of our outstanding stock options, restricted stock units, and performance stock units are considered anti-dilutive and excluded from the calculation of net loss per share. Accordingly, the treasury method was not used in determining the number of anti-dilutive stock options and restricted stock units.
Risks and Uncertainties	Risks and Uncertainties Considering factors such as our anticipated cash receipts from sales of grain and our product development and technology licensing efforts with partners, our anticipated cash burn rate, and our expense reduction efforts, we believe our cash, cash equivalents, and restricted cash as of June 30, 2021, will be sufficient to fund our operations for at least the next twelve months and into the second half of 2022. We anticipate that we will continue to generate losses for the next several years before revenue is enough to support our operating capital requirements. Until we can generate substantial cash flow, we expect to finance a portion of future cash needs through cash on hand, commercialization activities, which may result in various types of revenue streams from seed sales and future development agreements, trait licenses, and technology licenses, including upfront and milestone payments, annual license fees, and royalties, government or other third-party funding, and public or private equity or debt financings. However, additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in enough amounts or on terms acceptable to us, we may have to significantly delay, scale back, or discontinue the development or commercialization of our activities. Failure to receive additional funding could cause us to cease operations, in part or in full. If we raise additional funds through the issuance of additional debt or equity securities, it could result in dilution to our existing stockholders and increased fixed payment obligations, and these securities may have rights senior to those of our shares of common stock. Any of these events could significantly harm our business, financial condition, and prospects.

Financial Instruments Measure_2

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk (Tables)	6 Months Ended
	Jun. 30, 2021
Text Block [Abstract]
Summary of Fair Value Measurements and Financial Statement Presentation	The fair values of our financial instruments measured at fair value and their respective levels in the fair value hierarchy as of June 30, 2021, and December 31, 2020, were as follows: June 30, 2021 June 30, 2021 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Commodity derivative contracts $ 1 $ — $ — $ 1 $ — $ — $ — $ — Total $ 1 $ — $ — $ 1 $ — $ — $ — $ — December 31, 2020 December 31, 2020 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Short-term investments $ 11,698 $ — $ — $ 11,698 $ — $ — $ — $ — Commodity derivative contracts 467 — — 467 — — — — Total $ 12,165 $ — $ — $ 12,165 $ — $ — $ — $ —

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model	The estimated fair values of stock options granted, and the assumptions used for the Black-Scholes option pricing model were as follows: Six Months Ended June 30, 2021 2020 Estimated fair values of stock options granted $ 4.54 $ 5.19 Assumptions: Risk-free interest rate 0.6 % - 1.1 % 1.7 % Expected volatility 80.1 % - 82.0 % 77.4 % Expected term (in years) 5.5 - 6.5 6.9
Summary of Stock Option Activity	Information on stock option activity is as follows: Options Weighted- Options Weighted- Balance as of December 31, 2020 2,347,663 $ 10.15 4,621,173 $ 10.30 Granted 456,959 5.71 Exercised ( 61,372 ) 3.70 Forfeited or expired ( 550,110 ) 10.57 Balance as of June 30, 2021 2,412,501 $ 10.49 4,466,650 $ 9.89
Schedule of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised	Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Net cash proceeds $ 19 $ — $ 227 $ — Intrinsic value of options exercised $ 13 $ — $ 344 $ —
Summary of Activity of Restricted Stock Units	Information on restricted stock unit activity is as follows: Number of Weighted- Unvested balance at December 31, 2020 547,807 $ 9.49 Granted 234,504 5.61 Vested ( 69,323 ) 9.25 Forfeited ( 133,348 ) 12.49 Unvested balance at June 30, 2021 579,640 $ 7.26
Summary of Grant Date Fair Value of Restricted Stock Unit Awards Vested	The total grant-date fair value of restricted stock unit awards that vested is as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Grant-date fair value $ 390 $ 660 $ 641 $ 1,170
Summary of Stock-Based Compensation Granted As Deemed Dividends	We treat stock-based compensation awards granted to employees of Cellectis as deemed dividends. We recorded deemed dividends as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Deemed dividends from grants to Cellectis employees $ 107 $ 198 $ 28 $ 422
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to stock option awards is as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Stock-based compensation expense $ 800 $ 1,246 $ 405 $ 2,252
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to restricted stock units is as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Stock-based compensation expense $ 228 $ 441 $ ( 521 ) $ 596
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to performance stock units is as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Stock-based compensation expense $ 51 $ 110 $ ( 255 ) $ 220

Leases, Other Commitments, an_2

Leases, Other Commitments, and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2021
Lease Cost [Abstract]
Summary of Rent Expense from Operating Leases	Rent expense from operating leases was as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Rent expense from operating leases $ 11 $ 23 $ 24 $ 47

Supplemental Information (Table

Supplemental Information (Tables)	6 Months Ended
	Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Certain Balance Sheet Amounts	Certain balance sheet amounts are as follows: As of June 30, As of December 31, In Thousands 2021 2020 Accounts Receivable: Accounts receivable $ 3,819 $ 4,317 Receivables from growers 175 570 Allowance for doubtful accounts — — Total $ 3,994 $ 4,887
Schedule of Certain Statements of Operations Amounts	Certain statements of operations amounts are as follows: Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Stock compensation expense: Research and development $ 417 $ 488 $ 809 $ 807 Selling, general, and administrative 662 1,309 ( 1,180 ) 2,261 Total $ 1,079 $ 1,797 $ ( 371 ) $ 3,068 Three Months Ended June 30, Six Months Ended June 30, In Thousands 2021 2020 2021 2020 Interest, net: Interest expense $ ( 359 ) $ ( 371 ) $ ( 719 ) $ ( 743 ) Interest income 2 525 16 499 Total $ ( 357 ) $ 154 $ ( 703 ) $ ( 244 )
Schedule of Certain Statements of Balance sheet and cash flows amounts	Certain balance sheet and statements of cash flows amounts are as follows: As of June 30, As of December 31, As of June 30, In Thousands 2021 2020 2020 Cash, cash equivalents, restricted cash, and short-term investments: Cash and cash equivalents $ 17,489 $ 17,299 $ 3,875 Restricted cash 393 393 393 Non-current restricted cash 598 597 1,040 Total cash, cash equivalents, and restricted cash 18,480 18,289 5,308 Short-term investments — 11,698 29,942 Total $ 18,480 $ 29,987 $ 35,250

Financial Instruments Measure_3

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk - Summary of Fair Value Measurements and Financial Statement Presentation (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets		$ 12,165
Short Term Investments [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	$ 1	11,698
Commodity Derivative Contracts [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	1	467
Level 1 [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets		12,165
Level 1 [Member] | Short Term Investments [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	1	11,698
Level 1 [Member] | Commodity Derivative Contracts [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	$ 1	$ 467

Financial Instruments Measure_4

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk - Additional Information (Detail) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Fair Value Non-recurring [Member] | Level 2 [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair value of financing leases	$ 14.9	$ 15.2
Commodity Contracts [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Commodity derivative assets, notional amount	8
Unrealized gain loss on derivatives and commodity contracts	$ (1)

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail)	Jun. 30, 2021USD ($)
Cellectis [Member]
Related Party Transaction [Line Items]
Minimum net worth required	$ 300,000,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	Jul. 16, 2021	Jun. 30, 2021	Feb. 19, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares registered and available for grant		1,634,125
Common Stock Shares Issued		37,305,625		37,165,196
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares registered and available for grant		5,950,199
Common Stock Shares Issued	4,299,904
Calyxt, Inc. Equity Employee Inducement Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock Shares Issued	600,000
Mr. Blome [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected benefit to earnings from recapture of non-cash stock compensation expense			$ (2.5)

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model (Detail) - Stock Options [Member] - $ / shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair values of stock options granted	$ 4.54	$ 5.19
Risk-free interest rate		1.70%
Expected volatility		77.40%
Expected term (in years)		6 years 10 months 24 days
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.60%
Expected volatility	80.10%
Expected term (in years)	5 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.10%
Expected volatility	82.00%
Expected term (in years)	6 years 6 months

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Options - Additional Information (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2021USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to non-vested stock options	$ 6.7
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options priced at fair market value, percent	100.00%
Stock option expiration period	10 years
Weighted average remaining contractual term	5 years 9 months 18 days
Aggregate intrinsic value of options outstanding and exercisable	$ 0.4
2017 Omnibus Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	3 years
2017 Omnibus Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	6 years
Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense, expected recognition weighted-average period	28 months

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock Option Activity (Detail)	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options Exercisable, Beginning Balance | shares	2,347,663
Options Exercisable, Ending Balance | shares	2,412,501
Weighted-Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 10.15
Weighted-Average Exercise Price Per Share, Ending Balance | $ / shares	$ 10.49
Options Outstanding, Beginning Balance | shares	4,621,173
Options Outstanding, Granted | shares	456,959
Options Outstanding, Exercised | shares	(61,372)
Options Outstanding, Forfeited or expired | shares	(550,110)
Options Outstanding, Ending Balance | shares	4,466,650
Weighted-Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 10.30
Weighted-Average Exercise Price Per Share, Granted | $ / shares	5.71
Weighted-Average Exercise Price Per Share, Exercised | $ / shares	3.70
Weighted-Average Exercise Price Per Share, Forfeited or expired | $ / shares	10.57
Weighted-Average Exercise Price Per Share, Ending Balance | $ / shares	$ 9.89

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-Based Compensation Expense Related to Stock Option Awards (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,079	$ 1,797	$ 371	$ 3,068
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 800	$ 1,246	$ 405	$ 2,252

Stock-Based Compensation - Su_4

Stock-Based Compensation - Summary of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Net cash proceeds	$ 19	$ 0	$ 227	$ 0
Intrinsic value of options exercised	$ 13	$ 0	$ 344	$ 0

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units - Additional Information (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2021USD ($)
2017 Omnibus Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
2017 Omnibus Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	6 years
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to restricted stock units	$ 2.1
Unrecognized stock-based compensation expense, expected recognition weighted-average period	24 months
Restricted Stock Units [Member] | 2017 Omnibus Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Restricted Stock Units [Member] | 2017 Omnibus Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years

Stock-Based Compensation - Su_5

Stock-Based Compensation - Summary of Activity of Restricted Stock Units (Detail) - Restricted Stock Units [Member]	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock units outstanding, Unvested beginning balance | shares	547,807
Number of restricted stock units outstanding, Granted | shares	234,504
Number of restricted stock units outstanding, Vested | shares	(69,323)
Number of restricted stock units outstanding, Forfeited | shares	(133,348)
Number of restricted stock units outstanding, Unvested ending balance | shares	579,640
Weighted-average grant date fair value, Unvested beginning balance | $ / shares	$ 9.49
Weighted-average grant date fair value, Granted | $ / shares	5.61
Weighted-average grant date fair value, Vested | $ / shares	9.25
Weighted-average grant date fair value, Forfeited | $ / shares	12.49
Weighted-average grant date fair value, Unvested ending balance | $ / shares	$ 7.26

Stock-Based Compensation - Su_6

Stock-Based Compensation - Summary of Grant Date Fair Value of Restricted Stock Unit Awards Vested (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant-date fair value	$ 390	$ 660	$ 641	$ 1,170

Stock-Based Compensation - Su_7

Stock-Based Compensation - Summary of Stock-Based Compensation Expenses Related to Restricted Stock Units (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,079	$ 1,797	$ 371	$ 3,068
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 228	$ 441	$ (521)	$ 596

Stock-Based Compensation - Su_8

Stock-Based Compensation - Summary of Stock-Based Compensation Granted as Deemed Dividends (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Nonemployee Restricted Stock Units [Member] | Cellectis [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deemed dividends from grants to Cellectis employees	$ 107	$ 198	$ 28	$ 422

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance Stock Units - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted		1,634,125
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted		5,950,199
Performance Stock Units [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Increase in common stock starting price	$ 12.48
Unrecognized stock-based compensation expense related to performance stock units		$ 0.6
Unrecognized stock-based compensation expense, expected recognition weighted-average period		36 months
Performance Stock Units [Member] | Tranche One [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	50.00%
Performance Stock Units [Member] | Tranche Two [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	100.00%
Performance Stock Units [Member] | Tranche Three [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	120.00%
Performance Stock Units [Member] | Mr. Blome [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Benefit from forfeiture of stock		166,667
Performance Stock Units [Member] | Three Executive Officers [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted	311,667

Stock-Based Compensation - Su_9

Stock-Based Compensation - Summary of Stock-Based Compensation Expenses Related to Performance Stock Units (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,079	$ 1,797	$ 371	$ 3,068
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 51	$ 110	$ (255)	$ 220

Leases, Other Commitments, an_3

Leases, Other Commitments, and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Other Commitments [Line Items]
Restricted cash	$ 393	$ 393	$ 393
Forward purchase noncancelable commitments amount	$ 6,800
Equipment [Member]
Other Commitments [Line Items]
Lease term	4 years
Restricted cash	$ 1,000

Leases, Other Commitments, an_4

Leases, Other Commitments, and Contingencies - Summary of Rent Expense from Operating Leases (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Operating Leases Rent Expense [Abstract]
Rent expense from operating leases	$ 11	$ 23	$ 24	$ 47

Supplemental Information - Summ

Supplemental Information - Summary of Certain Balance Sheet Amounts (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Accounts Receivable:
Accounts receivable	$ 3,819	$ 4,317
Allowance for doubtful accounts	0	0
Total	3,994	4,887
Growers [Member]
Accounts Receivable:
Accounts receivable	$ 175	$ 570

Supplemental Information - Su_2

Supplemental Information - Summary of Certain Statements of Operations Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	$ 1,079	$ 1,797	$ 371	$ 3,068
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	417	488	809	807
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	$ 662	$ 1,309	$ 1,180	$ 2,261

Supplemental Information - Su_3

Supplemental Information - Summary of Components of Interest, Net (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Interest expense	$ (359)	$ (371)	$ (719)	$ (743)
Interest income	2	525	16	499
Total	$ (357)	$ 154	$ (703)	$ (244)

Supplemental Information - Su_4

Supplemental Information - Summary of Certain Statements of Balance Sheet and Cash Flows Amounts (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Cash and cash equivalents	$ 17,489	$ 17,299	$ 3,875
Restricted cash	393	393	393
Non-current restricted cash	598	597	1,040
Total cash, cash equivalents, and restricted cash	18,480	18,289	5,308	$ 60,038
Short-term investments	0	11,698	29,942
Total	$ 18,480	$ 29,987	$ 35,250

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) - USD ($) $ in Thousands	Apr. 08, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Apr. 19, 2020
Debt Instrument [Line Items]
Gain on extinguishment of Payroll Protection Program Loan		$ 1,528	$ 0	$ 1,528	$ 0
PPP loan
Debt Instrument [Line Items]
Loan, face amount						$ 1,500
Forgiveness eligibility description				In order to be eligible for forgiveness, the proceeds of the PPP loan were required to be applied to certain eligible expenses, including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments, with not more than 40 percent of the amount applied to non-payroll costs.
Description of loan forgiveness status	We applied the proceeds from the PPP loan toward qualifying expenses. On October 21, 2020, as modified December 29, 2020, we applied for forgiveness of the full principal amount and all accrued interest. On April 8, 2021, we were notified by the SBA that the full principal amount and all accrued interest of the PPP loan had been forgiven.
Gain on extinguishment of Payroll Protection Program Loan				$ 1,500